secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001628280-23-007305
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI Q4 revenue $71M (+36.6% YoY), net loss narrows; beats revised 2022 guidance
-------------------------------------------------------------------------------

- Q4 2022 revenue $71M (+36.6% YoY); gross profit $16M (+87.6% YoY); net loss $9.5M vs $10.2M prior year.
- Adjusted EBITDA loss improved to $(4.6)M from $(5.6)M in Q4 2021.
- Ended FY2022 with $132M cash; completed $110M Deerfield investment in Aug 2022.
- Surpassed top end of revised 2022 guidance for revenue, gross profit, and adjusted EBITDA.
- Market count expanded to 15 from 10; capitated membership added 100k+ lives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000162828023007305/0001628280-23-007305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000162828023007305/toi-20230309.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-007305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer